Marcenia Aldridge
Family · Summit, MSNPI 1508815713
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,500 of the $15,702 with a category attached, or 86.0%. AbbVie accounts for 90.6% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $14,239 and has fallen 96.8% since, to $462 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $106.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Novo Nordisk$270
- Lundbeck LLC$180
- Pfizer$171
- Supernus Pharmaceuticals, Inc.$151
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$95
- plus $612 from 21 others
What the payments were for
- Speaking & faculty fees$13,50086%
- Food & beverage$2,18814%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $14,224 |
| Novo Nordisk | 17 | $270 |
| Lundbeck LLC | 5 | $180 |
| Pfizer | 11 | $171 |
| Supernus Pharmaceuticals, Inc. | 2 | $151 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $95 |
| Lilly USA, LLC | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Dexcom, Inc. | 3 | $46 |
| Amgen | 3 | $43 |
| Abbott | 3 | $41 |
| Merck | 3 | $41 |
| IBSA Pharma Inc. | 1 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| AstraZeneca | 2 | $27 |
| Averitas Pharma Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Novartis | 1 | $19 |
| Tris Pharma Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,702 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $131,896 |
| EliquisApixaban | 117 | $119,628 |
| JanuviaSitagliptin Phosphate | 94 | $106,512 |
| JardianceEmpagliflozin | 77 | $99,293 |
| MounjaroTirzepatide | 61 | $76,311 |
| AptiomEslicarbazepine Acetate | 25 | $51,433 |
| TrulicityDulaglutide | 19 | $50,045 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 209 | $42,832 |
| VraylarCariprazine Hcl | 20 | $41,940 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $35,477 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 118 | $34,502 |
| LinzessLinaclotide | 27 | $32,659 |
| XareltoRivaroxaban | 27 | $28,437 |
| TradjentaLinagliptin | 18 | $26,177 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $23,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $270 | $131,89692 claims |
| PfizerEliquis, Abrysvo, Premarin | $171 | $130,915158 claims |
| Lilly USA, LLCMounjaro, Trulicity | $70 | $126,35680 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $125,47095 claims |
| GSKShingrix, Trelegy Ellipta, Arexvy | $21 | $112,811361 claims |
| MerckJanuvia | $41 | $106,51294 claims |
| AbbVieVraylar, Linzess | $14,224 | $74,59947 claims |
| AstraZenecaFarxiga, Symbicort | $27 | $34,84978 claims |
| NovartisEntresto | $19 | $15,68811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Summit
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
- Andrea WallaceOlive Branch$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.